Shopping Cart
- Remove All
Your shopping cart is currently empty
HAMI 3379
Catalog No. T64205Cas No. 1245653-57-9
Alias HAMI3379
HAMI 3379 (HAMI3379) is a selective cysteinyl leukotriene receptor 2 (CysLT2) antagonist that dose- and time-dependently attenuates brain damage and inhibits microglial cell inflammation following focal cerebral ischemia in rats and attenuates ischemia-like neuronal damage by inhibiting microglial activation.
HAMI 3379
Catalog No. T64205Alias HAMI3379Cas No. 1245653-57-9
HAMI 3379 (HAMI3379) is a selective cysteinyl leukotriene receptor 2 (CysLT2) antagonist that dose- and time-dependently attenuates brain damage and inhibits microglial cell inflammation following focal cerebral ischemia in rats and attenuates ischemia-like neuronal damage by inhibiting microglial activation.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $138 | 35 days | |
| 5 mg | $590 | 35 days | |
| 10 mg | $1,050 | 35 days | |
| 25 mg | $2,280 | 35 days |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "HAMI 3379"
Montelukast sodium
MK0476
T1677L151767-02-1
Montelukast sodium (MK0476) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.
- $41
Size
QTY
Bestatin
Cited
Ubenimex
T125758970-76-6
Bestatin (Ubenimex) competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Ubenimex is a microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage, and bone marrow stem cell as well as stimulates the release of interleukin-1 and -2, thus further enhances its antitumor activity.
- $48
Size
QTY
CitedTebufelone
T68155112018-00-5In house
Tebufelone is a potent in vitro inhibitor of CO , a novel non-steroidal anti-inflammatory drug (NSAID) belonging to the di-tert-butylphenol (DTBP) class that has shown potent anti-inflammatory, analgesic and anti-reticulitis properties in various animal models. Tebufelone potently inhibits the formation of prostaglandins (PGE2) and blocks the formation of lipoxygenase pathway products [leukotriene (LTB4)] in rat macrophages (IC50 = 20 microM) and human whole blood (IC50 = 22 microM) in vitro. = 20 microM) and human whole blood (IC50 = 22 microM) from the formation of lipoxygenase pathway products [leukotriene (LTB4)] in vitro.
- $52
Size
QTY
LTβR-IN-1
T118862189366-77-4In house
LTβR-IN-1 is a potent and selective lymphin β receptor (LTβR) inhibitor with a selective inhibitory effect on the nuclear translocation of p52 of TNF12A, without affecting the nuclear translocation of p65 mediated by the TNF-α receptor. It inhibits p52 nuclear translocation stimulated by TWEAK or Anti-LTβR with an IC50 of 10 μM and regulates the NF-kB signaling pathway in a ligand-independent manner.
- $30
Size
QTY
Ticolubant
T28974154413-61-3In house
Ticolubant is orally active leukotriene B4 antagonist with high affinity for the human neutrophil LTB4 receptor (Ki = 0.78 nM), blocks LTB4-induced Ca2+ migration with an IC50 of 6.6 ± 1.5 nM, and shows topical anti-inflammatory activity in a mouse model of skin inflammation.
- $210
Size
QTY
LTB4-IN-1
Anti-inflammatory agent 2
T10917133012-00-7In house
LTB4-IN-1 (Anti-inflammatory agent 2) with IC50 of 70 nM is an inhibitor of leukotriene synthesis (LTB4).
- $291
Size
QTY
Moxilubant HCl
Moxilubant hcl(146978-48-5 Free base)
T68108L146957-32-6
Moxilubant HCl is a small molecule leukotriene B4 receptor 1 (LTB4R) antagonist for the treatment of immune system disorders, skin and musculoskeletal disorders, and may be used in studies of psoriasis and rheumatoid arthritis.
- $195
Size
QTY
Croconazole
T987877175-51-0In house
Croconazole exhibited dose-dependent inhibitory activity on the 5-lipoxygenase (5-LOX) of neutrophils. Croconazole is an antimycotic agent. The IC50s for the synthesis of leukotriene B4 (LTB4) and 5-hydroxyeicosatetraenoic acid (5-HETE) is 7.8 +/- 1.7 and
- $52
Size
QTY
Montelukast Cited
Singular
T1677158966-92-8
Montelukast (Singular) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.
- $29
Size
QTY
CitedLinetastine
TMK-688, TMK688, TMK 688
T25737159776-68-8In house
Linetastine (TMK-688) is a 5-lipoxygenase inhibitor (5-LOX) that inhibits leukotriene production and antagonizes the effects of histamine.Linetastine is used in studies of asthma, atherosclerosis, and peptic ulcers.
- $130
Size
QTY
FPL 55712
T2278740785-97-5In house
FPL 55712 is a leukotriene receptor and SRS-A antagonist that inhibits bronchoconstriction and can be used in studies of asthma and coronary artery thrombosis.
- $86
Size
QTY
Ontazolast
BIRM-270
T68119147432-77-7In house
Ontazolast is a small molecule leukotriene B4 receptor (LTB4R) antagonist for the treatment of immune system disorders and respiratory diseases.Ontazolast is a candidate compound for the treatment of asthma.
- $85
Size
QTY
Select Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | HAMI 3379 (HAMI3379) is a selective cysteinyl leukotriene receptor 2 (CysLT2) antagonist that dose- and time-dependently attenuates brain damage and inhibits microglial cell inflammation following focal cerebral ischemia in rats and attenuates ischemia-like neuronal damage by inhibiting microglial activation. |
| Targets&IC50 | LTD4:3.8 nM, LTC4:4.4 nM |
| In vitro | HAMI 3379 effectively antagonizes LTD4- and LTC4-induced intracellular calcium mobilization in a CysLT2 receptor reporter cell line, with IC50 values of 3.8 nM and 4.4 nM, respectively. In contrast, HAMI 3379 shows minimal potency (IC50 > 10000 nM) in a recombinant CysLT1 receptor cell line and displays no agonistic activity in either CysLT receptor cell line.[1] |
| In vivo | 0.025-0.4 mg/kg HAMI 3379, intraperitoneally, was able to significantly reduce infarct volume and decrease the percent increase in the ischemic hemisphere to contralateral hemisphere ratio over the dose range of 0.1-0.4 mg/kg. Administration of 0.1 mg/kg HAMI 3379, intraperitoneal, at 0 and 1 hour after reperfusion was effective in reducing infarct volume, alleviating cerebral edema, decreasing neurologic function scores, and enhancing grip angle. [2] |
| Alias | HAMI3379 |
| Molecular Weight | 595.72 |
| Formula | C34H45NO8 |
| Cas No. | 1245653-57-9 |
Storage & Solubility Information
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (134.29 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy HAMI 3379 | purchase HAMI 3379 | HAMI 3379 cost | order HAMI 3379 | HAMI 3379 chemical structure | HAMI 3379 in vivo | HAMI 3379 in vitro | HAMI 3379 formula | HAMI 3379 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.